{
    "title": "Machine Learning Modeling Of SiRNA Structure-Potency Relationship With Applications Against Sars-Cov-2 Spike Gene. (arXiv:2401.12232v1 [q-bio.BM])",
    "abstract": "The pharmaceutical Research and development (R&D) process is lengthy and costly, taking nearly a decade to bring a new drug to the market. However, advancements in biotechnology, computational methods, and machine learning algorithms have the potential to revolutionize drug discovery, speeding up the process and improving patient outcomes. The COVID-19 pandemic has further accelerated and deepened the recognition of the potential of these techniques, especially in the areas of drug repurposing and efficacy predictions. Meanwhile, non-small molecule therapeutic modalities such as cell therapies, monoclonal antibodies, and RNA interference (RNAi) technology have gained importance due to their ability to target specific disease pathways and/or patient populations. In the field of RNAi, many experiments have been carried out to design and select highly efficient siRNAs. However, the established patterns for efficient siRNAs are sometimes contradictory and unable to consistently determine t",
    "link": "http://arxiv.org/abs/2401.12232",
    "context": "Title: Machine Learning Modeling Of SiRNA Structure-Potency Relationship With Applications Against Sars-Cov-2 Spike Gene. (arXiv:2401.12232v1 [q-bio.BM])\nAbstract: The pharmaceutical Research and development (R&D) process is lengthy and costly, taking nearly a decade to bring a new drug to the market. However, advancements in biotechnology, computational methods, and machine learning algorithms have the potential to revolutionize drug discovery, speeding up the process and improving patient outcomes. The COVID-19 pandemic has further accelerated and deepened the recognition of the potential of these techniques, especially in the areas of drug repurposing and efficacy predictions. Meanwhile, non-small molecule therapeutic modalities such as cell therapies, monoclonal antibodies, and RNA interference (RNAi) technology have gained importance due to their ability to target specific disease pathways and/or patient populations. In the field of RNAi, many experiments have been carried out to design and select highly efficient siRNAs. However, the established patterns for efficient siRNAs are sometimes contradictory and unable to consistently determine t",
    "path": "papers/24/01/2401.12232.json",
    "total_tokens": 843,
    "translated_title": "机器学习建模SiRNA结构与效力关系及其在Sars-Cov-2 Spike基因上的应用",
    "translated_abstract": "制药研发过程漫长且昂贵，将近十年时间才能将一种新药带到市场上。然而，生物技术、计算方法和机器学习算法的进步具有改革药物发现的潜力，可以加快进程并改善患者的结果。COVID-19疫情进一步加速和深化了对这些技术的潜力的认识，特别是在药物重用和疗效预测方面。与此同时，非小分子治疗模式如细胞疗法、单克隆抗体和RNA干扰技术因其能够针对特定疾病途径和/或患者人群而变得重要。在RNA干扰领域，已进行了许多实验以设计和选择高效的siRNA。然而，针对高效siRNA的已建立模式有时矛盾并且无法一致地确定。",
    "tldr": "机器学习模型揭示了SiRNA结构与效力关系，为抗击Sars-Cov-2 Spike基因提供了应用前景。"
}